|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUPR1 |
Gene summary for NUPR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUPR1 | Gene ID | 26471 |
| Gene name | nuclear protein 1, transcriptional regulator | |
| Gene Alias | COM1 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O60356 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26471 | NUPR1 | GSM4909280 | Human | Breast | Precancer | 7.74e-03 | -6.64e-01 | 0.0305 |
| 26471 | NUPR1 | GSM4909285 | Human | Breast | IDC | 2.16e-15 | -5.48e-01 | 0.21 |
| 26471 | NUPR1 | GSM4909286 | Human | Breast | IDC | 8.47e-14 | -4.74e-01 | 0.1081 |
| 26471 | NUPR1 | GSM4909293 | Human | Breast | IDC | 1.75e-03 | -2.19e-01 | 0.1581 |
| 26471 | NUPR1 | GSM4909294 | Human | Breast | IDC | 6.77e-11 | -6.94e-02 | 0.2022 |
| 26471 | NUPR1 | GSM4909296 | Human | Breast | IDC | 7.11e-14 | 2.49e-01 | 0.1524 |
| 26471 | NUPR1 | GSM4909297 | Human | Breast | IDC | 4.11e-22 | -3.53e-01 | 0.1517 |
| 26471 | NUPR1 | GSM4909298 | Human | Breast | IDC | 7.79e-06 | -3.12e-01 | 0.1551 |
| 26471 | NUPR1 | GSM4909304 | Human | Breast | IDC | 1.46e-14 | 4.55e-01 | 0.1636 |
| 26471 | NUPR1 | GSM4909306 | Human | Breast | IDC | 6.09e-31 | 5.75e-01 | 0.1564 |
| 26471 | NUPR1 | GSM4909308 | Human | Breast | IDC | 3.50e-18 | -5.19e-01 | 0.158 |
| 26471 | NUPR1 | GSM4909311 | Human | Breast | IDC | 2.60e-35 | -7.24e-02 | 0.1534 |
| 26471 | NUPR1 | GSM4909312 | Human | Breast | IDC | 3.41e-08 | 4.86e-02 | 0.1552 |
| 26471 | NUPR1 | GSM4909317 | Human | Breast | IDC | 6.19e-18 | -6.35e-01 | 0.1355 |
| 26471 | NUPR1 | GSM4909318 | Human | Breast | IDC | 3.03e-09 | -8.96e-01 | 0.2031 |
| 26471 | NUPR1 | GSM4909319 | Human | Breast | IDC | 3.43e-49 | -2.48e-01 | 0.1563 |
| 26471 | NUPR1 | GSM4909320 | Human | Breast | IDC | 4.30e-03 | -1.02e-01 | 0.1575 |
| 26471 | NUPR1 | GSM4909321 | Human | Breast | IDC | 2.11e-12 | -1.00e-02 | 0.1559 |
| 26471 | NUPR1 | brca2 | Human | Breast | Precancer | 9.45e-09 | 3.70e-01 | -0.024 |
| 26471 | NUPR1 | brca3 | Human | Breast | Precancer | 4.27e-09 | 4.05e-01 | -0.0263 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006163110 | Oral cavity | LP | purine nucleotide metabolic process | 122/4623 | 396/18723 | 3.10e-03 | 2.11e-02 | 122 |
| GO:0009150110 | Oral cavity | LP | purine ribonucleotide metabolic process | 114/4623 | 368/18723 | 3.41e-03 | 2.28e-02 | 114 |
| GO:000918519 | Oral cavity | LP | ribonucleoside diphosphate metabolic process | 39/4623 | 106/18723 | 3.64e-03 | 2.42e-02 | 39 |
| GO:004814513 | Oral cavity | LP | regulation of fibroblast proliferation | 31/4623 | 80/18723 | 3.69e-03 | 2.44e-02 | 31 |
| GO:004603118 | Oral cavity | LP | ADP metabolic process | 34/4623 | 90/18723 | 3.93e-03 | 2.56e-02 | 34 |
| GO:001605215 | Oral cavity | LP | carbohydrate catabolic process | 53/4623 | 154/18723 | 4.22e-03 | 2.70e-02 | 53 |
| GO:000616518 | Oral cavity | LP | nucleoside diphosphate phosphorylation | 36/4623 | 99/18723 | 6.29e-03 | 3.71e-02 | 36 |
| GO:0043433 | Oral cavity | LP | negative regulation of DNA-binding transcription factor activity | 61/4623 | 185/18723 | 6.68e-03 | 3.89e-02 | 61 |
| GO:006145818 | Oral cavity | LP | reproductive system development | 128/4623 | 427/18723 | 6.91e-03 | 3.96e-02 | 128 |
| GO:0009135110 | Oral cavity | LP | purine nucleoside diphosphate metabolic process | 37/4623 | 103/18723 | 7.09e-03 | 3.98e-02 | 37 |
| GO:0009179110 | Oral cavity | LP | purine ribonucleoside diphosphate metabolic process | 37/4623 | 103/18723 | 7.09e-03 | 3.98e-02 | 37 |
| GO:004860817 | Oral cavity | LP | reproductive structure development | 127/4623 | 424/18723 | 7.31e-03 | 4.08e-02 | 127 |
| GO:004578715 | Oral cavity | LP | positive regulation of cell cycle | 96/4623 | 313/18723 | 9.08e-03 | 4.85e-02 | 96 |
| GO:200123326 | Oral cavity | EOLP | regulation of apoptotic signaling pathway | 99/2218 | 356/18723 | 1.25e-16 | 1.25e-13 | 99 |
| GO:009719326 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway | 84/2218 | 288/18723 | 1.29e-15 | 7.05e-13 | 84 |
| GO:000989625 | Oral cavity | EOLP | positive regulation of catabolic process | 118/2218 | 492/18723 | 2.32e-14 | 9.26e-12 | 118 |
| GO:003133125 | Oral cavity | EOLP | positive regulation of cellular catabolic process | 106/2218 | 427/18723 | 4.63e-14 | 1.63e-11 | 106 |
| GO:200124226 | Oral cavity | EOLP | regulation of intrinsic apoptotic signaling pathway | 54/2218 | 164/18723 | 8.03e-13 | 2.09e-10 | 54 |
| GO:004593625 | Oral cavity | EOLP | negative regulation of phosphate metabolic process | 105/2218 | 441/18723 | 1.05e-12 | 2.46e-10 | 105 |
| GO:001056325 | Oral cavity | EOLP | negative regulation of phosphorus metabolic process | 105/2218 | 442/18723 | 1.22e-12 | 2.60e-10 | 105 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05202 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
| hsa052021 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
| hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| hsa052026 | Lung | IAC | Transcriptional misregulation in cancer | 40/1053 | 193/8465 | 6.90e-04 | 5.90e-03 | 3.92e-03 | 40 |
| hsa0520211 | Lung | IAC | Transcriptional misregulation in cancer | 40/1053 | 193/8465 | 6.90e-04 | 5.90e-03 | 3.92e-03 | 40 |
| hsa052022 | Lung | AIS | Transcriptional misregulation in cancer | 39/961 | 193/8465 | 2.15e-04 | 2.41e-03 | 1.54e-03 | 39 |
| hsa052023 | Lung | AIS | Transcriptional misregulation in cancer | 39/961 | 193/8465 | 2.15e-04 | 2.41e-03 | 1.54e-03 | 39 |
| hsa052027 | Prostate | BPH | Transcriptional misregulation in cancer | 53/1718 | 193/8465 | 9.56e-03 | 2.92e-02 | 1.81e-02 | 53 |
| hsa0520212 | Prostate | BPH | Transcriptional misregulation in cancer | 53/1718 | 193/8465 | 9.56e-03 | 2.92e-02 | 1.81e-02 | 53 |
| hsa0520221 | Prostate | Tumor | Transcriptional misregulation in cancer | 59/1791 | 193/8465 | 1.22e-03 | 5.26e-03 | 3.26e-03 | 59 |
| hsa0520231 | Prostate | Tumor | Transcriptional misregulation in cancer | 59/1791 | 193/8465 | 1.22e-03 | 5.26e-03 | 3.26e-03 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUPR1 | SNV | Missense_Mutation | c.208G>A | p.Ala70Thr | p.A70T | O60356 | protein_coding | tolerated(0.59) | benign(0.006) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| NUPR1 | SNV | Missense_Mutation | c.187N>G | p.Arg63Gly | p.R63G | O60356 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AZ-6603-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NUPR1 | SNV | Missense_Mutation | novel | c.80C>T | p.Ser27Phe | p.S27F | O60356 | protein_coding | deleterious(0.04) | benign(0.024) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUPR1 | SNV | Missense_Mutation | novel | c.278N>T | p.Arg93Met | p.R93M | O60356 | protein_coding | tolerated(0.09) | possibly_damaging(0.73) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| NUPR1 | SNV | Missense_Mutation | novel | c.203N>A | p.Ala68Asp | p.A68D | O60356 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| NUPR1 | SNV | Missense_Mutation | novel | c.148N>G | p.Thr50Ala | p.T50A | O60356 | protein_coding | tolerated(0.75) | benign(0) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUPR1 | SNV | Missense_Mutation | novel | c.267N>T | p.Gln89His | p.Q89H | O60356 | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NUPR1 | SNV | Missense_Mutation | rs780793494 | c.163N>C | p.Thr55Pro | p.T55P | O60356 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-55-7570-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NUPR1 | SNV | Missense_Mutation | novel | c.67N>C | p.Ser23Arg | p.S23R | O60356 | protein_coding | tolerated(0.34) | benign(0.316) | TCGA-91-6828-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NUPR1 | SNV | Missense_Mutation | novel | c.67N>T | p.Ser23Cys | p.S23C | O60356 | protein_coding | tolerated(0.18) | possibly_damaging(0.723) | TCGA-63-A5MH-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |